A Phase 1/2 Open-Label Dose-Escalation Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors

Brief description of study

The purpose of this research study is to learn about the effects of the study drug, NC318, when given as an investigational combination treatment for your cancer. “Investigational” means that the combination of drugs is new and is being studied to see if they are safe and effective (work well) at treating your cancer. The treatment NC318 have never been to people with your condition, so the research study will also find the best dose of NC318 to be given. This drug has not been approved by the US Food and Drug Administration (FDA) or any other health authority for the treatment of your cancer.


Clinical Study Identifier: s18-00797
ClinicalTrials.gov Identifier: NCT03665285
Principal Investigator: Jeffrey S. Weber
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.